Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Comparative Shedding Profiles of AAV2 vs. AAV5 Vectors Following Intravitreal Administration in NHP Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Comparative Shedding Profiles of AAV2 vs. AAV5 Vectors Following Intravitreal Administration in NHP Models

Comparative Shedding Profiles: AAV2 vs. AAV5 Following Intravitreal Administration

CELL & GENE | RNA | BIOLOGICS

Quantifying Ocular Biodistribution for Safer, More Predictable Gene Therapies.

What are the primary matrices for quantifying viral shedding after intravitreal AAV administration?
For ocular gene therapy programs, shedding analysis focuses on both local and systemic matrices. Key samples include aqueous humor, vitreous humor, and tears for local clearance assessment, alongside serum, plasma, urine, and feces to quantify any potential systemic vector distribution.
How does the choice between AAV2 and AAV5 impact the expected shedding profile in NHP models?
AAV2 exhibits strong tropism for retinal ganglion cells, while AAV5 effectively transduces photoreceptors and the retinal pigment epithelium. These distinct cellular interactions and trafficking pathways result in different clearance kinetics and shedding profiles. AAV2 may show more rapid clearance from the anterior chamber, whereas AAV5’s profile is dictated by its interaction with different retinal layers. Empirical data is required to define these differences for a specific construct.
Which bioanalytical assays are required for a GxP-compliant viral shedding study?
Quantitative polymerase chain reaction (qPCR) or droplet digital PCR (ddPCR) are the standard assays for quantifying vector DNA in collected matrices. These methods provide the necessary sensitivity and specificity to meet regulatory expectations for biodistribution and shedding studies under GxP standards.
What is the regulatory significance of viral shedding data for an IND submission?
Viral shedding data is a core component of the environmental risk assessment within an Investigational New Drug (IND) application. Regulators require this information to evaluate the potential for vector transmission to untreated individuals. A well-controlled study provides the definitive dataset to inform this biosafety evaluation.

The selection of an adeno-associated virus (AAV) serotype for intravitreal delivery directly influences vector biodistribution and shedding kinetics, an integral dataset for any IND-enabling safety package. AAV2 and AAV5, two common serotypes for ocular gene therapies, exhibit distinct shedding profiles that must be empirically characterized. This analysis is fundamental to de-risking clinical development and satisfying regulatory biosafety requirements.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Characterizing Vector Biodistribution in Ocular Gene Therapy

Intravitreal administration is designed to deliver a therapeutic vector directly to the target retinal tissue, yet quantifying vector clearance and potential systemic exposure remains a primary objective of the preclinical safety program. The anatomical and physiological similarities of the non-human primate eye to that of humans make it the definitive model for generating translationally relevant biodistribution and shedding data.

A robust study design isolates and quantifies vector DNA in all relevant biological matrices over a defined time course. This provides a clear understanding of the vector’s behavior post-administration, informing both safety assessments and potential dose-dependent toxicities.

Serotype-Specific Shedding Kinetics: AAV2 vs. AAV5

While both AAV2 and AAV5 are effective for retinal transduction, their cellular tropism and surface properties lead to different biological interactions. These differences must be understood to build a comprehensive safety profile.

Characteristic AAV2 AAV5
Primary Retinal Target Retinal Ganglion Cells (RGCs) Photoreceptors, RPE
Known Immunogenicity Higher prevalence of pre-existing NAbs Lower prevalence of pre-existing NAbs
Transduction Pathway Heparan Sulfate Proteoglycan Receptor Sialic Acid Receptor
Anticipated Shedding Route Primarily via aqueous humor turnover Clearance through RPE, potential for low-level systemic exposure

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Implications for Preclinical Program Design

Understanding vector distribution is vital for mitigating potential toxicities, a principle highlighted in studies involving high-dose systemic administration where unexpected adverse events were observed [PMID: 29378426]. Even with localized delivery, a comprehensive non-target tissue biodistribution analysis is necessary.

Research also shows that AAV vector DNA can exhibit significant structural heterogeneity following in vivo transduction [PMID: 20113166]. This reinforces the need for highly specific and validated quantitative assays to accurately measure vector DNA copies during shedding studies, ensuring the data reflects the true biological concentration.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

GxP-Compliant Bioanalysis for IND Submission

All bioanalytical work supporting regulatory filings must be conducted in a GxP-compliant environment. Our services support preclinical programs conducted under high standards of animal welfare in AAALAC-accredited facilities. In our >100,000 sq ft facility, we perform the required GxP assays to generate data packages that meet global regulatory standards.

Our approach is built on scientific rigor and regulatory awareness:

  • Validated Assays: We utilize qualified and validated qPCR and ddPCR assays for sensitive vector DNA quantification.

  • Regulatory Track Record: Our scientific leadership has contributed to a 100% IND success rate for client programs since 2019, a legacy of excellence continued at Franklin Biolabs since our 2024 launch. This expertise helps guide programs toward an 18-24 month IND timeline.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities